Lanadelumab 300mg/2ml solution for injection vials
NHS hospitals in England used £19,735,380 of indicative cost of Lanadelumab 300mg/2ml solution for injection vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 7.7% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Lanadelumab 300mg/2ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Lanadelumab 300mg/2ml solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Barts Health Nhs Trust | £11,476,080 |
| University Hpls North Midlands Nhs Trust | £3,340,980 |
| Western Sussex Hospitals Nhs Found Trust | £2,906,280 |
| University Hpls Of Leicester Nhs Trust | £484,380 |
| Dudley Group Nhs Foundation Trust | £434,700 |
| Cambridge Univ Hosp Nhs Foundation Trust | £347,760 |
| King's College Hpl Nhs Foundation Trust | £273,240 |
| Univ Hpls Bristol Nhs Foundation Trust | £223,560 |
| Epsom & St Helier Univ Hpls Nhs Trust | £149,040 |
| Guy's & St Thomas' Nhs Foundation Trust | £74,520 |
The primary-care picture
Lanadelumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Lanadelumab medicine page.